• BASF profit €322M up in Q1 2017 BASF

    BASF, a Germany based chemical company has reported results for Q1 2017.

  • FDA warns 14 USA companies selling fake treatments for cancer

    The U.S. Food and Drug Administration today posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer.

  • ANDA approvals time reduction can reduce drug costs

    Girish Malhotra, President of EPCOT International, and CPhI Worldwide Annual Industry Report member, discusses the necessity of time reduction for ANDA approvals, arguing that if the current approval time can be reduced from ten months to three months, drug costs will decrease.

  • J&J, Takeda among interested in Brazil’s Hypermarcas, sources say A sign marks a building on Novartis' campus in Cambridge, Massachusetts, U.S., February 28, 2017. Picture taken February 28, 2017. REUTERS/Brian Snyder

    Johnson & Johnson <JNJ.N>, Novartis AG <NOVN.S> and Takeda Pharmaceutical Co Ltd <4502.T> have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA <HYPE3.SA>, two people with knowledge of the matter said on Monday

  • Servier, CTI BioPharma expand Pixuvri deal CTI BioPharma

    Servier and CTI BioPharma Corp. will expand their agreement regarding Pixuvri, which will give Servier rights to sell it anywhere but the USA. For that, Servier will pay $12 million to CTI BioPharma, and possibly another €76 million from sales and regulatory milestone payments as well as royalties on net product sales.

  • Orexigen closer to weight loss product deal in canada Valeant Pharmaceuticals International Inc

    Orexigen Therapeutics said that Health Canada has accepted to review a New Drug Submission for marketing approval of its products Contrave (naltrexone HCl and bupropion HCl).

  • Amgen, Novartis expand mutual work on migraine Migraine

    Amgen and Novartis have formed a coalition that will be expanded and, as they hope, bring easier launching of a migraine related product, the USA-based company said late Monday.

  • Bristol-Myers and Transgene testing combination of their cancer drugs opdivo

    Bristol-Myers Squibb and Transgene have entered a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1.

  • Generic competition offsets Novartis’s 1Q sales, net income 15% down Novartis

    Novartis’ has posted a first quarter net income down 15% citing a net charge related to the discontinuation of RLX030 ($-0.2 billion), as well as the decline in core operating income.

  • Bayer parners up with Goodbye Malaria to end malaria Bayer

    Bayer has partnered up with Goodbye Malaria to support the objectives of Ending Malaria for Good in Southern Africa.

Booking.com IN